This study is looking at whether adding fluconazole (an antifungal medicine) to standard IL-23 therapies (like risankizumab, guselkumab, or ustekinumab) can improve treatment for Crohn's disease. You might be able to join if you are at least 18 years old and have mild to moderate Crohn's disease, and are starting or increasing your dose of an IL-23 therapy. The main goal is to see if more people achieve a clinical response (meaning their symptoms improve) after 12 weeks when taking fluconazole with their IL-23 therapy compared to IL-23 therapy alone. The current status of this study is unclear, and it plans to enroll 120 participants.

Study design

This is an interventional study where participants will be randomly assigned to receive either fluconazole or a placebo (an inactive pill) along with their IL-23 therapy. It aims to enroll 120 participants.

What's involved

You would take oral fluconazole or placebo capsules for 14 days. You would also have standard clinic visits at 2 weeks and 12 weeks after starting treatment, with blood, stool, and oral swab samples collected at several time points. Biopsies may also be collected if you have an endoscopy.

Compensation

Not stated in the trial record.

Follow-up

Your clinical response will be measured at Week 12 after starting fluconazole or placebo.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.